

# 2022 TCT Nursing Agenda ILNA Cheat Sheet

Thursday 2/3/22 5.5 CNE	Topics	Objectives	ILNA
6:30 – 8:15am 8:30-9:00am	<b>Breakfast</b>		
	<b>Welcome &amp; Awards</b>		
9:00-10:15 (1.25CNE)	<b>Pharmacy Update</b>	<ol style="list-style-type: none"> <li>1. Summarize new oral and IV therapies for the treatment of leukemia, lymphoma and multiple myeloma and discuss their role in relation to transplant.</li> <li>2. Discuss side effects and monitoring recommendations for these new therapies.</li> </ol>	<ul style="list-style-type: none"> <li>• Foundations of Transplant</li> <li>• Cellular Collection, Prep Regimens, and Infusion</li> <li>• Early post-transplant education and management</li> <li>• Symptom Management</li> <li>• Treatment</li> <li>• Care of the Peds Hem/Onc Patient</li> </ul>
10:15-10:30	<b>Break</b>		
10:30-11:00 (.5 CNE)	<b>Best Abstracts</b>		
11:00-12:00 (1 CNE)	<b>Practice Guidelines and SIG update</b>	<ol style="list-style-type: none"> <li>1. Discuss the need for standardized nursing guidelines for practice in the blood and marrow transplant specialty.</li> <li>2. Identify gaps in practice where standardized guidelines can improve care.</li> </ol>	Professional Performance
12:00-1:15	<b>Lunch</b>		
1:30 – 2:30 (1 CNE)	<b>Onc emergencies in the Transplant and Cellular Therapy patient</b>	<ol style="list-style-type: none"> <li>1. Define diagnostic criteria for cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS) including grading scale.</li> <li>2. Discuss management of CRS/ICANS/TLS</li> </ol>	<ul style="list-style-type: none"> <li>• Oncologic Emergencies</li> <li>• Symptom Management</li> <li>• Early post-transplant management and education</li> </ul>

2:35 – 3:05 (.5 CNE) 3:05 – 3:15 3:15 – 4:30 (1.25)		including novel therapies.	
	<b>Abstracts</b>		
	<b>Break</b>		
	<b>Survivorship</b>	<ol style="list-style-type: none"> <li>1. Review common late effects experienced by pediatric BMT survivors.</li> <li>2. Understand how and when to screen for late effects.</li> <li>3. Review models of survivorship care and identify resources for clinicians and survivors.</li> </ol>	<ul style="list-style-type: none"> <li>• Care of the Peds Hem/Onc patient</li> <li>• Psychosocial</li> <li>• Quality of Life</li> <li>• Survivorship</li> <li>• Symptom Management</li> <li>• Late Post-transplant management</li> <li>• Professional Performance</li> </ul>
<b>Friday 2/4/22</b> <b>6.25 CNE</b> 6:30 – 8:15 8:00 – 8:30 (.5 CNE) 08:45 – 10:00 (1.25 CNE) 10:05 – 10:30 10:30 – 12:00 (1.5 CNE) 12:00-1:30 1:30-2:45 (1.25 CNE)			
	<b>Breakfast</b>		
	<b>Abstracts</b>		
	<b>Hot Topics: DEI in Transplant and Cellular Therapy</b>	<ol style="list-style-type: none"> <li>1. Understanding the research efforts to address the lack of donors for BIPOC.</li> <li>2. Discuss how the NMDP is working to add more diverse donors to the registry.</li> </ol>	<ul style="list-style-type: none"> <li>• Professional Performance</li> <li>• Oncology nursing practice</li> <li>• Care of the Peds Hem/Onc patient</li> </ul>
	<b>Break</b>		
	<b>Roundtables</b>	<ol style="list-style-type: none"> <li>1.State one new practice change you could implement in your practice.</li> <li>2. Discuss new opportunities to improve patient care in your practice.</li> </ol>	Professional performance
<b>Lunch</b>			
<b>Transplant in the LGBTQI+ community</b>	<ol style="list-style-type: none"> <li>1. Describe strategies to provide an inclusive, safe and supportive care environment for LGBTQIA+ patients, families and staff.</li> <li>2. Understand the increased cancer risks in this population.</li> <li>3. Discuss disparities in access to healthcare</li> </ol>	<ul style="list-style-type: none"> <li>• Quality of Life</li> <li>• Psychosocial</li> <li>• Care Continuum</li> <li>• Professional performance</li> <li>• Foundations of Transplant</li> <li>• Early Post transplant management and education</li> <li>• Late post transplant management and education</li> </ul>	

		and provide recommendations to address those disparities.	
2:45 – 3:15 (.5 CNE)	<b>Abstracts</b>		
3:15 – 3:30	<b>Break</b>		
3:30 – 4:45 (1.25 CNE)	<b>Post-Transplant and IEC Vaccinations</b>	<ol style="list-style-type: none"> <li>1. Review the “who, when, and how of feasible and effective post-transplant vaccination”</li> <li>2. Clarify the established vaccine guidelines for transplant survivors of all ages.</li> <li>3. Examine COVID vaccination in the transplant patient population.</li> </ol>	<ul style="list-style-type: none"> <li>• Health maintenance</li> <li>• Late post-transplant management and education</li> <li>• Quality of Life</li> <li>• Professional Performance</li> </ul>
<b>Saturday 2/5/22</b>			
<b>7.25 CNE</b>			
6:30 – 8:15	<b>Breakfast</b>		
8:30-10:00 (1.5 CNE)	<b>Roundtables</b>	1.State one new practice change you could implement in your practice. 2. Discuss new opportunities to improve patient care in your practice.	Professional Performance
10:00 – 10:15	<b>Break</b>		
10:15 –10:45 (.5 CNE)	<b>Abstracts</b>		
10:45 – 12:00 (1.25 CNE)	<b>Updates in GVHD</b>	<ol style="list-style-type: none"> <li>1. Review signs, symptoms and grading of acute and chronic GVHD.</li> <li>2. Understand new treatments and discuss the pros/cons of each.</li> </ol>	<ul style="list-style-type: none"> <li>• Symptom Management</li> <li>• Early Post Transplant Management and Education</li> <li>• Late Post Transplant Management and Education</li> <li>• Treatment</li> <li>• Care of the Peds Hem/Onc Patient</li> <li>• Care Continuum</li> </ul>
12:00 – 1:30	<b>Lunch</b>		
1:30 – 2:45 (1.25 CNE)	<b>Adult and Pediatric Breakouts - CAR Tcell therapy updates</b>	<p>Peds: Sickle cell Adult: Multiple Myeloma</p> <ol style="list-style-type: none"> <li>1. Describe the established role of autologous hematopoietic cell</li> </ol>	<ul style="list-style-type: none"> <li>• Foundations of Transplant</li> <li>• Care of the Peds Hem/Onc Patient</li> <li>• Cellular Collection, Prep Regimens, and Infusion</li> <li>• Quality of Life</li> <li>• Professional Performance</li> <li>• Care Continuum</li> <li>• Treatment</li> </ul>

		<p>transplantation (HCT) in patients with multiple myeloma (MM) in the era of modern induction therapies</p> <ol style="list-style-type: none"> <li>2. Discuss novel therapies (eg. Immunotherapy) in the treatment of MM</li> <li>3. Understand the importance of timely referral of MM patients for HCT</li> <li>4. Discuss disparities in access to HCT for patients with MM and provide recommendations to address those disparities</li> </ol>	
2:45 – 3:00	<b>Break</b>		
3:00 – 3:30 (.5 CNE)	<b>Abstracts</b>		
3:30 – 4:45 (1.25 CNE)	<b>Responding to Crisis: Examples and Advice for Working with Aggressive Patients</b>	Waiting on objectives.	<ul style="list-style-type: none"> <li>• Psychosocial</li> <li>• Quality of Life</li> <li>• Professional Performance</li> </ul>
6:00 – 7:00 (1 CNE)	<b>Posters</b>		